PMID- 19035176
OWN - NLM
STAT- MEDLINE
DCOM- 20100408
LR  - 20211203
IS  - 0253-2727 (Print)
IS  - 0253-2727 (Linking)
VI  - 29
IP  - 7
DP  - 2008 Jul
TI  - [Prognostic significance of p53 and ATM gene deletion in patients with chronic 
      lymphocytic leukemia].
PG  - 450-3
AB  - OBJECTIVE: To explore the prognostic significance of p53 and ATM gene deletion in 
      patients with chronic lymphocytic leukemia (CLL). METHODS: Interphase 
      fluorescence in situ hybridization (FISH) and probes of LSI p53 and LSI ATM were 
      used to detect p53 and ATM gene deletion in 80 patients with CLL. p53 and ATM 
      gene deletion and their association with some prognostic factors were analyzed. 
      The Kaplan-Meier method was used to calculate survivals, and results were 
      compared using the Log-rank test. Multivariate COX regression analysis was used 
      to assess associations between survival and potential risk factors. RESULTS: Out 
      of the 80 CLL patients, p53 gene deletion was found in 14 (17.5%) cases, ATM gene 
      deletion in 9 (11.3% ) cases, and both the two genes deletion in 3 (3.8%) cases. 
      There was no significant differences of p53 and ATM gene deletion rates in sex, 
      age, Binet stages, peripheral lymphocyte count, and the levels of LDH, beta2-MG, 
      and ZAP-70. The p53 and ATM gene deletion rates were higher in the group of CD38 
      high expression than that in the group of low expression (P=0.025 and P=0.001). 
      Among 41 patients who received fludarabine containing protocol, none of the nine 
      cases with p53 and/or ATM gene deletion achieved complete response (CR), while 12 
      of 32 (37.5%) cases without the gene deletion achieved CR. The survival time was 
      shorter in patients with p53 gene deletion (P<0.01). There was no association 
      between outcome and ATM gene deletion (P=0.556). On multivariate analysis by COX 
      regression, p53 gene deletion and CD38 expression (P=0.014 and P=0.017, 
      respectively) were found to be independent factors in predicting survival. 
      CONCLUSION: CLL patients with p53 and/or ATM gene deletion had poor therapeutic 
      effect, and hence poor prognosis.
FAU - Xu, Wei
AU  - Xu W
AD  - Department of Hematology, the First Affiliated Hospital of Nanjing Medical 
      University, Jiangsu Province Hospital, Nanjing 210029, China.
FAU - Li, Jian-yong
AU  - Li JY
FAU - Li, Li
AU  - Li L
FAU - Wu, Yu-jie
AU  - Wu YJ
FAU - Yu, Hui
AU  - Yu H
FAU - Shen, Qiu-dan
AU  - Shen QD
FAU - Qiu, Hong-xia
AU  - Qiu HX
LA  - chi
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Xue Ye Xue Za Zhi
JT  - Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
JID - 8212398
RN  - 0 (Cell Cycle Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - 0 (Tumor Suppressor Proteins)
RN  - EC 2.7.11.1 (ATM protein, human)
RN  - EC 2.7.11.1 (Ataxia Telangiectasia Mutated Proteins)
RN  - EC 2.7.11.1 (Protein Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Ataxia Telangiectasia Mutated Proteins
MH  - Cell Cycle Proteins/*genetics
MH  - DNA-Binding Proteins/*genetics
MH  - Female
MH  - *Gene Deletion
MH  - Humans
MH  - Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Protein Serine-Threonine Kinases/*genetics
MH  - Treatment Outcome
MH  - Tumor Suppressor Protein p53/*genetics
MH  - Tumor Suppressor Proteins/*genetics
EDAT- 2008/11/28 09:00
MHDA- 2010/04/09 06:00
CRDT- 2008/11/28 09:00
PHST- 2008/11/28 09:00 [pubmed]
PHST- 2010/04/09 06:00 [medline]
PHST- 2008/11/28 09:00 [entrez]
PST - ppublish
SO  - Zhonghua Xue Ye Xue Za Zhi. 2008 Jul;29(7):450-3.